Filter by Year:

August 19, 2026 | CELL & GENE THERAPY REVIEW

RNA’S comeback tour

June 12, 2026 | Cell & Gene: The Podcast

Why In Vivo Therapies Are Moving Toward the Clinic with Ascidian Therapeutics’ Dr. Mike Ehlers

June 4, 2026 | Pharmaceutical Technology

Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership

June 3, 2026 | Axios

Ascidian lands up to $1.9B Lilly pact for kidney disease gene medicines

June 3, 2026 | BioPharma Dive

Lilly, Ascidian link up in RNA exon editing pact

June 3, 2026 | BioSpace

Lilly targets kidney disease with Ascidian’s RNA exon editors for up to $1.9B

June 3, 2026 | Biotech TV

Ascidian and Lilly signed a collaboration today to use Ascidian’s RNA exon editing platform for monogenic kidney diseases, potentially worth up to $1.9 billion in milestones

June 3, 2026 | BioXconomy

Ascidian Therapeutics’ RNA rewriting technology lands $1.9bn Lilly partnership

June 3, 2026 | Bloomberg

Lilly, Ascidian Strike RNA-Editing Pact For Up to $1.9 Billion

June 3, 2026 | Boston Business Journal

Eli Lilly inks deal worth up to $1.9B with Boston biotech for kidney disease work